Treatment of heparin-associated XXXX and @entity715 with low molecular weight heparin ( @entity11270 ).

@entity1 @entity1158 @entity882 @entity63 @entity1423 @entity11270 @entity1151 @entity1150 @entity2026 @entity715 @entity204
This report concerns 34 cases of heparin-associated @entity882 in which standard heparin has been systematically replaced by LMW heparin @entity11270 Choay. There were 21 @entity1 and 13 @entity1 , mean age, 69 years. Twenty-six of the 34 cases had @entity715 complications. All of the @entity1 were treated by standard heparin of porcine mucosal origin, in most cases for prevention of @entity1150 and @entity1151 . Twenty-six cases occurred along with orthopedic and traumatologic surgery (especially for total hip replacement, 15 cases). Four cases involved vascular surgery and three involved medical @entity715 . Standard heparin treatment was always replaced by LMW heparin @entity11270 . Initial doses were 0.30 ml three times daily, later increased to obtain @entity2026 . Surgical procedures (embolectomy and vena cava filter) were carried out when necessary. Five @entity1 had thrombolytic treatment (urokinase) in conjunction with LMW heparin. The overall results were 31 recoveries, but with seven severe sequelae (three amputations and four @entity1158 ) most often attributable to the first @entity63 attack, and three @entity204 . For the last 16 @entity1 , indirect @entity1423 tests were performed (control platelet-rich plasma plus @entity1 platelet-poor plasma plus LMW heparin): nine cases had negative tests, with nine recoveries and seven cases had positive tests, with five recoveries and two @entity204 .(ABSTRACT TRUNCATED AT 250 WORDS)
